Skip to main content
. 2021 Dec 10;161(5):1167–1179. doi: 10.1016/j.chest.2021.11.035

Figure 4.

Figure 4

A-C, Bar graphs showing exacerbation rates. A, Exacerbation rate declined during the PY from 0.133 exacerbations/person/y to 0.053 exacerbations/person/y (P < .01). B, Exacerbation rates adjusted for ETI therapy and other variables demonstrated no significant difference in the PPY vs PY (0.065 vs 0.054 exacerbations/person/y; P = .68). C, All antibiotic use, including both IV and oral antibiotics, adjusted for ETI therapy and other variables, decreased from 0.612 occurrences/person/y during the PPY to 0.366 occurrences/person/y during in PY (P = .02). ETI = elexacaftor/tezacaftor/ivacaftor; PPY = prepandemic year; PY = pandemic year.